US · Healthcare · Drug Manufacturers - General
EPS came in at 2.41 against a street estimate of 2.20 — a beat of 9.5%.
Analysts rate Novartis AG ADR a hold (2 buy, 9 hold, 2 sell out of 13) with an average price target of $156.56.
| Fund | Stake |
|---|---|
| Fisher Asset Management, LLC | 0.82% |
| Morgan Stanley - Brokerage Accounts | 0.45% |
| Dimensional Fund Advisors, Inc. | 0.43% |
| PRIMECAP Management Company | 0.35% |
| The Goldman Sachs Group Inc | 0.34% |
| Loomis, Sayles & Company LP | 0.28% |
| Bank of America Corp | 0.26% |
| Franklin Templeton Inc | 0.18% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $4.77 / share ex-date Mar 11, 2026 · pay Mar 16, 2026 | 2026-03-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Novartis AG ADR — free to start.
Google PlayApp StoreData updated 2026-09-18.